Article Cited by others


Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis

Frieri Marianne, Heuser William, Bliss Joshua

Year : 2015| Volume: 6| Issue : 2 | Page no: 71-76

   This article has been cited by
1 Adverse Events Associated with Belimumab Therapy in Systemic Lupus Erythematosus
Leong Tung Ong, Nicholas Ming Zher Chee
Current Treatment Options in Rheumatology. 2021; 7(3): 272
[Pubmed]  [Google Scholar] [DOI]
2 Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis
Simin Jamaly, Mehrdad Rakaee, Reza Abdi, George C. Tsokos, Kristin Andreassen Fenton
Autoimmunity Reviews. 2021; : 102980
[Pubmed]  [Google Scholar] [DOI]
3 Implications the Role of miR-155 in the Pathogenesis of Autoimmune Diseases
Salar Pashangzadeh, Morteza Motallebnezhad, Fatemeh Vafashoar, Azadeh Khalvandi, Nazanin Mojtabavi
Frontiers in Immunology. 2021; 12
[Pubmed]  [Google Scholar] [DOI]
4 Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina
A Babini, A M Cappuccio, C Caprarulo, G Casado, A Eimon, H Figueredo, M A García, S Magri, P Mannucci, S Perez Rodriguez, B A Pons-Estel, E J Velozo, M Iglesias-Rodriguez, G Streger
Lupus. 2020; 29(11): 1385
[Pubmed]  [Google Scholar] [DOI]
5 Discovery and Qualification of Candidate Urinary Biomarkers of Disease Activity in Lupus Nephritis
Veronica G. Anania, Kebing Yu, Francesco Pingitore, Qingling Li, Christopher M. Rose, Peter Liu, Wendy Sandoval, Ann E. Herman, Jennie R. Lill, W. Rodney Mathews
Journal of Proteome Research. 2019; 18(3): 1264
[Pubmed]  [Google Scholar] [DOI]
6 Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases
Charles J. Malemud
Current Pharmacology Reports. 2018;
[Pubmed]  [Google Scholar] [DOI]
7 All-Trans-Retinoic Acid Augments the Histopathological Outcome of Neuroinflammation and Neurodegeneration in Lupus-Prone MRL/lpr Mice
Michelle H. Theus,Joshua B. Sparks,Xiaofeng Liao,Jingjing Ren,Xin M. Luo
Journal of Histochemistry & Cytochemistry. 2017; 65(2): 69
[Pubmed]  [Google Scholar] [DOI]
8 Treatment of membranous nephropathy: time for a paradigm shift
Piero Ruggenenti,Fernando C. Fervenza,Giuseppe Remuzzi
Nature Reviews Nephrology. 2017;
[Pubmed]  [Google Scholar] [DOI]
9 Systemic lupus erythematous exacerbation following cessation of belimumab treatment: comments on the article by Furer et al
S Carbajal1,C Zamora-Martínez,S Prieto-González,LF Quintana,G Espinosa1,R Cervera
Scandinavian Journal of Rheumatology. 2017; 46(3): 250
[Pubmed]  [Google Scholar] [DOI]
10 Belimumab in the management of systemic lupus erythematosus – an update
Vladimir Tesar,Zdenka Hruskova
Expert Opinion on Biological Therapy. 2017; 17(7): 901
[Pubmed]  [Google Scholar] [DOI]
11 Lupus nephritis and B-cell targeting therapy
Matthias Cassia,Federico Alberici,Maurizio Gallieni,David Jayne
Expert Review of Clinical Immunology. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
12 Lupus eritematoso sistémico a día de hoy
José Mario Sabio
Medicina Clínica. 2016; 146(4): 160
[Pubmed]  [Google Scholar] [DOI]
13 Systemic lupus erythematosus and atherosclerosis: Review of the literature
Marianne Frieri,Heather Stampfl
Autoimmunity Reviews. 2016; 15(1): 16
[Pubmed]  [Google Scholar] [DOI]
14 MicroRNAs in the key events of systemic lupus erythematosus pathogenesis
Marketa Husakova
Biomedical Papers. 2016;
[Pubmed]  [Google Scholar] [DOI]
15 To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies
Annalisa Marcuzzi,Elisa Piscianz,Erica Valencic,Lorenzo Monasta,Liza Brumatti,Alberto Tommasini
International Journal of Molecular Sciences. 2015; 16(9): 21277
[Pubmed]  [Google Scholar] [DOI]
16 NF-?B in inflammation and renal diseases
Haisong Zhang,Shao-Cong Sun
Cell & Bioscience. 2015; 5(1)
[Pubmed]  [Google Scholar] [DOI]


Read this article